Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.56 |
| ▸ | HRH1 | P35367 | 3/20 | 0.51 |
| ▸ | CCR3 | P51677 | 2/20 | 0.51 |
| ▸ | DRD2 | P14416 | 3/20 | 0.46 |
| ▸ | DRD3 | P35462 | 3/20 | 0.46 |
| ▸ | NOS3 | P29474 | 1/20 | 0.44 |
| ▸ | NOS1 | P29475 | 1/20 | 0.44 |
| ▸ | NOS2 | P35228 | 1/20 | 0.44 |
| ▸ | TRPC6 | Q9Y210 | 2/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | HRH2 | P25021 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | TRPC3 | Q13507 | 1/20 | 0.41 |
| ▸ | TRPC7 | Q9HCX4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4228461 | 0.87 | HRH3 (0.57) | HRH3HRH1CCR3DRD2DRD3 | |
| SCHEMBL4233735 | 0.86 | HRH3 (0.56) | HRH3HRH1CCR3DRD2DRD3 | |
| SCHEMBL4233991 | 0.86 | HRH3 (0.56) | HRH3HRH1CCR3DRD2DRD3 | |
| SCHEMBL4233907 | 0.85 | HRH3 (0.53) | HRH3HRH1CCR3DRD2DRD3 | |
| SCHEMBL5864791 | 0.82 | HTR4 (0.47) | HRH3HRH1MAOAMAOBKDM4E | |
| SCHEMBL4237104 | 0.80 | HRH3 (0.85) | HRH3HRH1CCR3MAOAMAOB | |
| SCHEMBL4237246 | 0.78 | EPHX2 (0.51) | HRH1CCR3MAOAMAOB | |
| SCHEMBL4967327 | 0.78 | UTS2R (0.47) | HRH3HRH1CCR3TRPC6 | |
| SCHEMBL5864901 | 0.77 | MAPT (0.46) | MAOAMAOBKDM4E | |
| SCHEMBL4232384 | 0.77 | HRH3 (0.56) | HRH3HRH1CCR3NOS3NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090233910-A1 | Npy antagonists, preparation and uses | CEREP (FR) | 2009-09-17 | — | — | US | disclosed |
| EP-1879887-A2 | NPY ANTAGONISTS, PREPARATION AND USE | Cerep (FR) | 2008-01-23 | — | — | EP | disclosed |
| WO-2006108965-A2 | NPY ANTAGONISTS, PREPARATION AND USE | CEREP (FR) | 2006-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233910-A1 | Npy antagonists, preparation and uses | NPY1R, NPY5R, NPY2R | HRH3 210/4885HRH1 217/4885CCR3 1438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.